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RESEARCH LETTERAll that glisters is not COVID: Low
prevalence of seroconversion
against SARS-CoV-2 in a pediatric
cohort of patients with chilblain-like
lesionsFig 1. Typical chilblainlike lesions in a pediatric patient
enrolled in the study.To the Editor: On January 7, 2020, a novel corona-
virus, severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), was isolated in a patient affected by
interstitial pneumonia. As SARS-CoV2 infection has
spread worldwide, an increasing number of authors
have reported chilblainlike lesions as possible man-
ifestations of SARS-CoV-2 infection.1,2
To test this hypothesis, we performed serologic
and stool/rectal polymerase chain reaction tests in
a cohort of children who developed chilblainlike
lesions during the SARS-CoV-2 outbreak in Italy,
between March 8 and April 30, 2020.
Enrollment criteria are described in the
Supplemental material (available via Mendeley at
https://doi.org/10.17632/wzh2tyb46y.2).
During the enrollment period, 35 cases of chil-
blainlike lesions were eligible for the study. Twenty-
four patients agreed to serologic testing (68.6%).
All patients were white, mean age was 13 years
(range, 6-17 years), and the female to male ratio was
2:1. Twenty-two patients presented with chilblains
on the toes (Fig 1) and 2 lesions were located on the
heels, 6 patients developed blistering lesions, 83% of
lesions lasted more than 14 days, and 8% lasted less
than 1 week.
Two patients had known contact with SARS-
CoV-2epositive individuals, defined by positive
nasal swab result. Seven more patients had close
contact with someonewho presented symptoms that
might be SARS-CoV-2 related such as asthenia, loss of
smell (anosmia), cough, and prolonged fever. In 25%
of cases, at least 1 parent was a health worker.
Further details are available in the Supplemental
Results.
Chemiluminescence assay (Liaison SARS-CoV-2
IgG, Diasorin) was performed for all patients; 7
patients were tested with In3diagnostic ERADIKIT
COVID19, and the other 17 with EDI Novel
Coronavirus COVID-19.
A total of 3 patients (12.5%) tested positive via
both enzyme-linked immunosorbent assay and
chemiluminescence. In 1 patient (4.1%), enzyme-
linked immunosorbent assay test result was positive,
whereas chemiluminescence result was negative.
None of the 4 patients with positive results presentedJ AM ACAD DERMATOLwith fever, 50% had cough, and 25% presented with
transient diarrhea up to 14 days before skin lesion
appearance. All 4 patients had contact with a relative
who had confirmed SARS-CoV-2 infection (2 pa-
tients) or anosmia (2 patients). Fecal polymerase
chain reaction was tested in 4 patients (16.6%), and
no result was positive; rectal swab was performed in
17 patients (70.8%) and was positive in 1, which also
was positive at both serologic tests.
Finally, patients with chilblainlike lesions were
compared with a cohort of 24 SARS-CoV-2einfected
children. Table I shows the comparison between the
2 groups. Chilblain patients were significantly older
(13 vs 4 year; P\.001); fever was present in a limited
number of cases (16.7% vs 92%; P \ .001), and
certainty of exposure to SARS-CoV-2 was limited (8%
vs 56%; P\ .001).
According to our data, the hypothesis of a direct
etiologic link between SARS-CoV-2 and chilblain is
not confirmed by serologic tests; it is difficult to
assess whether in the 4 patients with positive
serology SARS-CoV-2 was involved in the pathogen-
esis of chilblainlike lesions. A limit of our study is the
absence of tissue biopsies, so our experimental
approach could not rule out the presence of virus
in patients’ lesions that may induce an interferon-I
response.3 As confirmed by other studies,4 the lown 2020 1
Table I. Comparison between pediatric cohorts with chilblainlike lesions and severe acute respiratory
syndrome coronavirus 2 infection
Epidemilogical characteristics and symptoms Chilblains SARS-CoV-2 infection* P value
No. of patients 24 25 NA
Age, y, (range) 13 (10.5e14) 3.8 (0.95e9) \.001
Female patient, no. (%) 15 (62.5) 8 (32) .04
Skin lesions, no. (%) 24 (100) 3 (12) \.001
Fever, no. (%) 4 (16.7) 23 (92) \.001
Cough, no. (%) 10 (41.7) 13 (52) .5
Conjunctivitis, no. (%) 3 (12.5) 0 .1
GI symptoms, no. (%) 5 (20.8) 6 (24) [.99
Certain exposure to SARS-CoV-2, no. (%) 2 (8.3) 14 (56) \.001
The differences between groups were analyzed with Mann-Whitney U test for continuous data and Fisher’s exact test for categoric data. All
tests were 2 tailed, and the significance was set at P\ .05.
GI, Gastrointestinal; NA, not available; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
*Twenty-two patients hospitalized and 3 evaluated in the emergency department at the Regina Margherita Children’s Hospital.
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n 2020
2 Letterprevalence (12.5%) of seropositive patients suggests
that other pathologic hypotheses should be consid-
ered to explain the recent outbreaks of chilblainlike
lesions worldwide.
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